NCT00106782

Brief Summary

This study will evaluate the effect of transcranial electrical polarization (TEP), also called direct current (DC) stimulation, on focal hand dystonia in people with writer's cramp. In dystonia, muscle spasms cause uncontrolled twisting and repetitive movement or abnormal postures. Focal dystonia involves just one part of the body, such as the hand, neck or face. When people with focal hand dystonia make small and repeated movements with their hands, there is extra activity in the part of the brain called the motor cortex. TEP is a method of brain stimulation that slows down the activity of the nerve cells in the motor cortex. This study may help researchers develop new ways to treat focal hand dystonia. People 18 years of age and older with focal hand dystonia may be eligible for this study. Participants have a neurological examination and are randomly assigned to one of two treatment groups: TEP or placebo stimulation. The TEP group receives stimulation to the parts of the brain used for hand movement, and the placebo group receives sham stimulation, which does not affect any area of the brain. There are three TEP/placebo sessions over a period of 7 to 10 days. The first session may last up to 2-1/2 hours; the other two sessions last 1-2 hours. For TEP, sponge electrodes are placed on the scalp and an electrical current is passed through the scalp and skull to the outer part of brain. Before and after each session, participants have a neurological examination, including an evaluation of the rate and severity of their movement problems. For this assessment, participants do a writing test while the electrical activity of their hand muscles is recorded using surface electromyography (EMG). For EMG, small metal disks (electrodes) filled with a conductive gel are taped to the skin over the muscles being tested. Patients are followed in the clinic the day after the end of TEP treatment for evaluation of their movement abilities and the effects of therapy, such as improvement of handwriting.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Mar 2005

Longer than P75 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 18, 2005

Completed
11 days until next milestone

First Submitted

Initial submission to the registry

March 29, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 30, 2005

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 14, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 14, 2010

Completed
Last Updated

July 2, 2017

Status Verified

May 14, 2010

Enrollment Period

5.2 years

First QC Date

March 29, 2005

Last Update Submit

June 30, 2017

Conditions

Keywords

ElectricalStimulationDystoniaBrainFocal Hand DystoniaFHD

Outcome Measures

Primary Outcomes (1)

  • The Fahn Dystonia Scale before and after real and placebo TEP course.

    1 week post-TEP

Study Arms (2)

1

OTHER

Real TEP

Procedure: Transcranial Electrical Polarization (TEP)

2

OTHER

Sham Stimulation

Procedure: Transcranial Electrical Polarization (TEP)

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects with focal hand dystonia 18 years old or older will be included.

You may not qualify if:

  • We will exclude subjects with:
  • Any significant medical or psychiatric illness (other than FHD).
  • Patients with a positive pregnancy test will be excluded because the effects of TEP on the fetus is unknown. A urine sample for pregnancy testing will be obtained prior to the TEP, and on the day of the first TEP session.
  • History of epilepsy.
  • Concurrent use of neuroleptic agents.
  • Any other licit or illicit drugs other that could lower the seizure threshold.
  • Metal implants.
  • Who have received botulinum toxin injection within 10 weeks of starting the protocol.
  • Secondary hand dystonia.
  • Mentally impaired patients having no capacity to provide their own consent will be excluded from the study because such patients may have difficulty performing the required test.
  • If participation in the study would, in the opinion of the investigators, cause undue risk or stress for reasons such as excessive fatigue, general frailty, or excessive apprehension.
  • Unable or unwilling to refrain from alcohol for 24 hours prior to study days.
  • Patients may continue taking muscle relaxants, artane and other anticholinergic drugs, L-DOPA and dopamine agonists.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Agnew WF, McCreery DB. Considerations for safety in the use of extracranial stimulation for motor evoked potentials. Neurosurgery. 1987 Jan;20(1):143-7. doi: 10.1097/00006123-198701000-00030.

    PMID: 3808255BACKGROUND
  • Antal A, Nitsche MA, Paulus W. External modulation of visual perception in humans. Neuroreport. 2001 Nov 16;12(16):3553-5. doi: 10.1097/00001756-200111160-00036.

    PMID: 11733710BACKGROUND
  • Chen R, Wassermann EM, Canos M, Hallett M. Impaired inhibition in writer's cramp during voluntary muscle activation. Neurology. 1997 Oct;49(4):1054-9. doi: 10.1212/wnl.49.4.1054.

    PMID: 9339689BACKGROUND

MeSH Terms

Conditions

DystoniaDystonia, Focal, Task-Specific

Condition Hierarchy (Ancestors)

DyskinesiasNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
NIH

Study Record Dates

First Submitted

March 29, 2005

First Posted

March 30, 2005

Study Start

March 18, 2005

Primary Completion

May 14, 2010

Study Completion

May 14, 2010

Last Updated

July 2, 2017

Record last verified: 2010-05-14

Locations